[
  {
    "ts": null,
    "headline": "Is Concentra Group Holdings Parent, Inc. (CON) Stock Outpacing Its Medical Peers This Year?",
    "summary": "Here is how Concentra Group (CON) and Boston Scientific (BSX) have performed compared to their sector so far this year.",
    "url": "https://finnhub.io/api/news?id=b1efc330efc1cc9030557b013b58509e96a92200d6a07eed623dad642c60f114",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752154803,
      "headline": "Is Concentra Group Holdings Parent, Inc. (CON) Stock Outpacing Its Medical Peers This Year?",
      "id": 135856147,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Here is how Concentra Group (CON) and Boston Scientific (BSX) have performed compared to their sector so far this year.",
      "url": "https://finnhub.io/api/news?id=b1efc330efc1cc9030557b013b58509e96a92200d6a07eed623dad642c60f114"
    }
  },
  {
    "ts": null,
    "headline": "Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?",
    "summary": "The average brokerage recommendation (ABR) for Boston Scientific (BSX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
    "url": "https://finnhub.io/api/news?id=06d158ab4a1555eb4cc9728908ef5b4afe7dae0ad00e1c0c9fde181907df7388",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752154202,
      "headline": "Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?",
      "id": 135856148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The average brokerage recommendation (ABR) for Boston Scientific (BSX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
      "url": "https://finnhub.io/api/news?id=06d158ab4a1555eb4cc9728908ef5b4afe7dae0ad00e1c0c9fde181907df7388"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
    "url": "https://finnhub.io/api/news?id=e8b0b8795dba0071d21a2197be5d282be8c6387ef0a512f1ddb03ba82297bd13",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752152402,
      "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
      "id": 135855658,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
      "url": "https://finnhub.io/api/news?id=e8b0b8795dba0071d21a2197be5d282be8c6387ef0a512f1ddb03ba82297bd13"
    }
  },
  {
    "ts": null,
    "headline": "ABT's FreeStyle Libre 3 Plus Now Available in Canada: Stock to Rise?",
    "summary": "Abbott debuts FreeStyle Libre 3 Plus in Canada, enhancing diabetes care with the world's smallest glucose sensor.",
    "url": "https://finnhub.io/api/news?id=81e67a3cf3e6b7939b538c15ebee833b2b5b4b119785c3f05520e5a948847878",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752150060,
      "headline": "ABT's FreeStyle Libre 3 Plus Now Available in Canada: Stock to Rise?",
      "id": 135855872,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Abbott debuts FreeStyle Libre 3 Plus in Canada, enhancing diabetes care with the world's smallest glucose sensor.",
      "url": "https://finnhub.io/api/news?id=81e67a3cf3e6b7939b538c15ebee833b2b5b4b119785c3f05520e5a948847878"
    }
  },
  {
    "ts": null,
    "headline": "Is it Worth Adding Boston Scientific Stock to Your Portfolio Now?",
    "summary": "BSX rides on strong MedSurg growth and strategic acquisitions amid currency headwinds.",
    "url": "https://finnhub.io/api/news?id=c0802c1b10c58592cfb536ec8f3a4ae554b44aa8eaceeb2df807fb1a06513018",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752149880,
      "headline": "Is it Worth Adding Boston Scientific Stock to Your Portfolio Now?",
      "id": 135855873,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "BSX rides on strong MedSurg growth and strategic acquisitions amid currency headwinds.",
      "url": "https://finnhub.io/api/news?id=c0802c1b10c58592cfb536ec8f3a4ae554b44aa8eaceeb2df807fb1a06513018"
    }
  },
  {
    "ts": null,
    "headline": "1 Healthcare Stock with Competitive Advantages and 2 to Be Wary Of",
    "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry has tumbled by 6%. This performance is a far cry from the S&P 500’s 7.5% ascent.",
    "url": "https://finnhub.io/api/news?id=527a27bd5bee5bc2e13c2e5fe08b02eec41a4053444344e1967fba157369d891",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752122244,
      "headline": "1 Healthcare Stock with Competitive Advantages and 2 to Be Wary Of",
      "id": 135851707,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry has tumbled by 6%. This performance is a far cry from the S&P 500’s 7.5% ascent.",
      "url": "https://finnhub.io/api/news?id=527a27bd5bee5bc2e13c2e5fe08b02eec41a4053444344e1967fba157369d891"
    }
  }
]